The Natural History of Pediatric Crohn Disease

  • James Markowitz


Inflammatory Bowel Disease Crohn Disease Postoperative Recurrence Pediatric Inflammatory Bowel Disease Small Bowel Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterol 1979;77(4 Pt 2):847–869.Google Scholar
  2. 2.
    Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterol 1984;86(2):249–266.Google Scholar
  3. 3.
    Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterol 2000;119:895–902.Google Scholar
  4. 4.
    Romano C, Cucchiara S, Barabino A, et al. Usefulness of ϖ-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn’s disease: A double-blind, randomized, placebo-controlled study. World J Gastroenterol 2005;11(45): 7118–7121.PubMedGoogle Scholar
  5. 5.
    Langholz E, Munkholm P, Krasilnikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997;32:139–147.Google Scholar
  6. 6.
    Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995l;30(7):699–706.Google Scholar
  7. 7.
    Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002;16(1):51–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and the risk for early surgery in pediatric-onset Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:1003–1009.PubMedCrossRefGoogle Scholar
  9. 9.
    Russell RK, Drummond HE, Nimmo EE, et al. Genotype-phenotype analysis in childhood-onset Crohn’s disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 2005;11(11):955–964.PubMedCrossRefGoogle Scholar
  10. 10.
    Vermeire S, Pierik M, Hlavaty T, et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn’s disease but not with susceptibility to IBD. Gastroenterol 2005;129(6): 1845–1853.CrossRefGoogle Scholar
  11. 11.
    Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol 2006;101(2):360–367.PubMedCrossRefGoogle Scholar
  12. 12.
    Kirschner BS. Growth and development in chronic inflammatory bowel disease. Acta Paediatr Scand Suppl 1990;366:98–104.PubMedGoogle Scholar
  13. 13.
    Markowitz J, Grancher K, Rosa J, et al. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;16(4):373–380.PubMedCrossRefGoogle Scholar
  14. 14.
    Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 1988;95(6):1523–1527.PubMedGoogle Scholar
  15. 15.
    Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121(2):255–260.PubMedCrossRefGoogle Scholar
  16. 16.
    Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994;35(3):360–362.PubMedCrossRefGoogle Scholar
  17. 17.
    Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1 year outcomes in newly diagnosed children with Crohn disease. Clin Gastroenterol Hepatol 2006;4(9): 1124–1129.PubMedCrossRefGoogle Scholar
  18. 18.
    Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn’s disease. Gastroenterology. 2006;130(4):1069–1077.PubMedCrossRefGoogle Scholar
  19. 19.
    Becker JM. Surgical therapy for ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am 1999;28(2):371–390, viii–ix.Google Scholar
  20. 20.
    Chardavoyne R, Flint GW, Pollack S, et al. Factors affecting recurrence following resection for Crohn’s disease. Dis Colon Rectum 1986;29(8):495–502.PubMedCrossRefGoogle Scholar
  21. 21.
    Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn’s disease. Italian Cooperative Study Group. Gastroenterology 1995;108:345–349.Google Scholar
  22. 22.
    Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid: Asacol) for the prevention of post-operative recurrence of Crohn disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994;8:35–43.Google Scholar
  23. 23.
    Rutgeerts P, Heile M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995;108:1617–1621.PubMedCrossRefGoogle Scholar
  24. 24.
    Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128(4):856–861.PubMedCrossRefGoogle Scholar
  25. 25.
    Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remissions with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterol 2004;127:723–729.CrossRefGoogle Scholar
  26. 26.
    Griffiths AM. Factors that influence the postoperative recurrence of Crohn’s disease in childhood. In Inflammatory Bowel Disease and Coeliac Disease in Children. Hadziselimovic F, Herzog B, Burgin-Wolff A (eds). Boston: Kluwer Academic Publishers, 1990, pp. 131–136.Google Scholar
  27. 27.
    Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990;336:357–359.PubMedCrossRefGoogle Scholar
  28. 28.
    Mellemkjaer L, Johansen C, Gridley G, et al. Crohn’s disease and cancer risk (Denmark). Cancer Causes and Control 2000;11:145–150.PubMedCrossRefGoogle Scholar
  29. 29.
    Jess T, Loftus EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterol 2006;130:1039–46.CrossRefGoogle Scholar
  30. 30.
    Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308–2312.PubMedCrossRefGoogle Scholar
  31. 31.
    Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54(8):1121–1125.PubMedCrossRefGoogle Scholar
  32. 32.
    Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 40:220–222.Google Scholar
  33. 33.
    Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;35:557–563.Google Scholar
  34. 34.
    Otley A, Griffiths AM, Hyams J, et al. Health-related quality of life in the first year following a diagnosis of pediatric inflammatory bowel disease. Inflamm Bowel Dis;12(8):684–691.Google Scholar
  35. 35.
    Rabbett H, Elbadri A, Thwaites R, et al. Quality of life in children with Crohn disease J Pediatr Gastroenterol Nutr 1996;23:528–533.PubMedCrossRefGoogle Scholar
  36. 36.
    Akobeng AK, Suresh-Babu MV, Firth D, et al. Quality of life in children with Crohn’s disease: a pilot study. J Pediatr Gastroenterol Nutr 1999;28:S37–S39.PubMedCrossRefGoogle Scholar
  37. 37.
    Moody G, Eaden JA, Mayberry JF. Social implications of childhood Crohn’s disease. J Pediatr Gastroenterol Nutr 1999;28:S43–S45.PubMedCrossRefGoogle Scholar
  38. 38.
    Ferguson A, Sedgwick DM, Drummond J, et al. Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life. Gut 1994;35:665–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995;30:699–706.PubMedGoogle Scholar
  40. 40.
    Farmer RG, Michener WM. Prognosis of Crohn’s disease with onset in childhood or adolescence. Dig Dis Sci 1979;24(10):752–757.PubMedCrossRefGoogle Scholar
  41. 41.
    Ferguson A, Sedgwick DM. Juvenile-onset inflammatory bowel disease: predictors of morbidity and health status in early adult life. J R Coll Physicians Lond 1994;28(3):220–227.PubMedGoogle Scholar
  42. 42.
    Besnard M, Jaby O, Mougenot JF, et al. Postoperative outcome of Crohn’s disease in 30 children. Gut 1998;43(5):634–638.PubMedGoogle Scholar
  43. 43.
    Baldassano RN, Han PD, Jeshion WC, et al. Pediatric Crohn’s disease: risk factors for postoperative recurrence. Am J Gastroenterol. 2001;96(7):2169–2176.PubMedCrossRefGoogle Scholar
  44. 44.
    Markowitz J, Markowitz JE, Bousvaros A, et al. Workshop report: prevention of postoperative recurrence in Crohn’s disease. J Pediatr Gastroenterol Nutr 2005;41(2):145–151.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • James Markowitz
    • 1
  1. 1.Division of Pediatric Gastroenterology, Schneider Children’s HospitalNYU School of Medicine, Attending Pediatrician, North Shore – LIJ Health SystemNew YorkUSA

Personalised recommendations